Marker Therapeutics Reports Positive Impact of Lymphodepletion on MAR-T Cells

The latest update is out from Marker Therapeutics ( (MRKR) ).

Marker Therapeutics has reported that lymphodepletion enhances the expansion and persistence of their MAR-T cells in patients with lymphoma, suggesting improved anti-tumor activity. The company has seen increased patient enrollment in their Phase 1 APOLLO study, indicating positive momentum and a promising trial trajectory, with plans to present expanded clinical data later this year.

The most recent analyst rating on (MRKR) stock is a Buy with a $12.50 price target. To see the full list of analyst forecasts on Marker Therapeutics stock, see the MRKR Stock Forecast page.

Spark’s Take on MRKR Stock

According to Spark, TipRanks’ AI Analyst, MRKR is a Neutral.

Marker Therapeutics is positioned in the biotechnology industry, characterized by high potential but also significant risks. The company exhibits strong revenue growth but faces challenges with profitability and cash flow. Technical indicators present a mixed outlook, with some potential for price reversals. The valuation reflects typical industry dynamics, favoring growth over profitability. Investors should be cautious, focusing on the company’s ability to manage cash flow and improve operational efficiencies to support future growth.

To see Spark’s full report on MRKR stock, click here.

More about Marker Therapeutics

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.

Average Trading Volume: 112,111

Technical Sentiment Signal: Sell

Current Market Cap: $12.79M

See more data about MRKR stock on TipRanks’ Stock Analysis page.